{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,1,4]],"date-time":"2025-01-04T18:40:27Z","timestamp":1736016027689,"version":"3.32.0"},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2006,1,1]]},"DOI":"10.1093\/ndt\/gfi113","type":"journal-article","created":{"date-parts":[[2005,10,5]],"date-time":"2005-10-05T03:07:51Z","timestamp":1128481671000},"page":"197-202","source":"Crossref","is-referenced-by-count":10,"title":["Evolution of the absorption profile of cyclosporine A in renal transplant recipients: a longitudinal study of the de novo and maintenance phases"],"prefix":"10.1093","volume":"21","author":[{"given":"Matthias","family":"B\u00fcchler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steve","family":"Chadban","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward","family":"Cole","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karsten","family":"Midtvedt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Thervet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans","family":"Prestele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Keown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2005,10,4]]},"reference":[{"key":"key\n\t\t\t\t20171012173145_BIB1","doi-asserted-by":"crossref","unstructured":"Srinivas TR, Meier-Kriesche H-U, Kaplan B. Pharmacokinetic principles of immunosuppressive drugs. Am J Transplant2005; 5: 207\u2013217","DOI":"10.1111\/j.1600-6143.2005.00748.x"},{"key":"key\n\t\t\t\t20171012173145_BIB2","doi-asserted-by":"crossref","unstructured":"Mahalati K, Belitsky P, West K. Approaching the therapeutic window for cyclosporine in kidney transplantation: a prospective study. J Am Soc Nephrol2001; 12: 828\u2013833","DOI":"10.1681\/ASN.V124828"},{"key":"key\n\t\t\t\t20171012173145_BIB3","doi-asserted-by":"crossref","unstructured":"International Neoral Renal Transplantation Study Group. Randomized, international study of cyclosporine microemulsion absorption profiling in renal transplantation with basiliximab immunoprophylaxis. Am J Transplant2002; 2: 157\u2013166","DOI":"10.1034\/j.1600-6143.2002.020207.x"},{"key":"key\n\t\t\t\t20171012173145_BIB4","doi-asserted-by":"crossref","unstructured":"Thervet E, Pfeffer P, Scolari MP et al. Clinical outcomes during the first three months posttransplant in renal allograft recipients managed by C2 monitoring of cyclosporine microemulsion. Transplantation2003; 76: 903\u2013908","DOI":"10.1097\/01.TP.0000089006.00653.64"},{"key":"key\n\t\t\t\t20171012173145_BIB5","doi-asserted-by":"crossref","unstructured":"Mahalati K, Belitsky P, Sketris I, West K, Panek R. Neoral monitoring by simplified sparse sampling area under the concentration\u2013time curve: its relationship to acute rejection and cyclosporine nephrotoxicity early after kidney transplantation. Transplantation1999; 68: 55\u201362","DOI":"10.1097\/00007890-199907150-00011"},{"key":"key\n\t\t\t\t20171012173145_BIB6","doi-asserted-by":"crossref","unstructured":"Karamperis N, Koefoed-Nielsen P, Bagger Sorensen A, Hojskov C, Poulsen J, Jorgensen K. Role of metabolites and calcineurin inhibition on C2 monitoring in renal transplant patients. Nephrol Dial Transplant2005; 20: 618\u2013621","DOI":"10.1093\/ndt\/gfh671"},{"key":"key\n\t\t\t\t20171012173145_BIB7","doi-asserted-by":"crossref","unstructured":"International Neoral Renal Transplantation Study Group. Cyclosporine microemulsion (Neoral\u00ae) absorption profiling and sparse-sample predictors during the first 3 months after renal transplantation. Am J Transplant2002; 2: 148\u2013156","DOI":"10.1034\/j.1600-6143.2002.020206.x"},{"key":"key\n\t\t\t\t20171012173145_BIB8","doi-asserted-by":"crossref","unstructured":"Cantarovich M, Besner JG, Barkun JS, Elstein E, Loertscher R. Two-hour cyclosporine level determination is the appropriate tool to monitor Neoral therapy. Clin Transplant1998; 12: 243\u2013249","DOI":"10.1111\/j.1399-0012.1998.tb01098.x"},{"key":"key\n\t\t\t\t20171012173145_BIB9","doi-asserted-by":"crossref","unstructured":"Trompeter R, Fitzpatrick M, Hutchinson C, Johnston A. Longitudinal evaluation of the pharmacokinetics of cyclosporin microemulsion (Neoral) in pediatric renal transplant recipients and assessment of C2 level as a marker for absorption. Ped Transplant2003; 7: 282\u2013288","DOI":"10.1034\/j.1399-3046.2003.00077.x"},{"key":"key\n\t\t\t\t20171012173145_BIB10","doi-asserted-by":"crossref","unstructured":"Einecke G, Mai I, Diekmann F, Fritsche L, Neumayer HH, Budde K. Cyclosporine absorption profiling and therapeutic drug monitoring using C(2) blood levels in stable renal allograft recipients. Transplant Proc2002; 34: 1738\u20131739","DOI":"10.1016\/S0041-1345(02)03003-8"},{"key":"key\n\t\t\t\t20171012173145_BIB11","doi-asserted-by":"crossref","unstructured":"Waiser J, Slowinski T, Brinker-Paschke A et al. Impact of the variability of cyclosporin A trough levels on long-term renal allograft function. Nephrol Dial Transplant2002; 17: 1310\u20131317","DOI":"10.1093\/ndt\/17.7.1310"},{"key":"key\n\t\t\t\t20171012173145_BIB12","doi-asserted-by":"crossref","unstructured":"Savoldi S, Maiorca R, Maderna M, Chiappini R, Corbetta G. Low intrapatient variability of blood cyclosporine levels is correlated with excellent graft survival. Transplant Proc1997; 29: 288\u2013289","DOI":"10.1016\/S0041-1345(96)00110-8"},{"key":"key\n\t\t\t\t20171012173145_BIB13","doi-asserted-by":"crossref","unstructured":"Einecke G, Mai I, Fritsche L et al. The value of C2 monitoring in stable renal allograft recipients on maintenance immunosuppression. Nephrol Dial Transplant2004; 19: 215\u2013222","DOI":"10.1093\/ndt\/gfg434"},{"key":"key\n\t\t\t\t20171012173145_BIB14","doi-asserted-by":"crossref","unstructured":"Stefoni S, Midtvedt K, Cole E et al. Efficacy and safety outcomes among de novo renal transplant recipients managed by C2 monitoring of cyclosporine microemulsion: results of a 12-month, randomized, multicenter study. Transplantation2005; 79: 577\u2013583","DOI":"10.1097\/01.TP.0000153158.91683.34"},{"key":"key\n\t\t\t\t20171012173145_BIB15","doi-asserted-by":"crossref","unstructured":"Canadian Neoral Renal Transplantation Study Group. Absorption profiling of cyclosporine microemulsion (Neoral) during the first 2 weeks after renal transplantation. Transplantation2001; 72: 1024\u20131032","DOI":"10.1097\/00007890-200109270-00008"},{"key":"key\n\t\t\t\t20171012173145_BIB16","doi-asserted-by":"crossref","unstructured":"Goto MA, Masuda SA, Kiuchi TB et al. CYP3A5*1-carrying graft liver reduces the concentration\/oral dose ratio of tacrolimus in recipients of living-donor liver transplantation. Pharmacogenetics2004; 14: 471\u2013478","DOI":"10.1097\/01.fpc.0000114747.08559.49"},{"key":"key\n\t\t\t\t20171012173145_BIB17","doi-asserted-by":"crossref","unstructured":"Lemahieu WP, Maes BD, Verbeke K, Vanrenterghem Y. CYP3A4 and P-glycoprotein activity in healthy controls and transplant patients on cyclosporin vs. tacrolimus vs. sirolimus. Am J Transplant2004; 4: 1514\u20131522","DOI":"10.1111\/j.1600-6143.2004.00539.x"},{"key":"key\n\t\t\t\t20171012173145_BIB18","doi-asserted-by":"crossref","unstructured":"Cole E, Deshpande R. The impact of cyclosporine on the development of immunosuppressive therapy: perspective from a transplant nephrologist involved with the development of C2. Transplant Proc2004; 36 [Suppl 2]: 408S\u2013413S","DOI":"10.1016\/j.transproceed.2004.01.041"},{"key":"key\n\t\t\t\t20171012173145_BIB19","doi-asserted-by":"crossref","unstructured":"Cole E, Maham N, Cardella C et al. Clinical benefits of Neoral C2 monitoring in the long-term management of renal transplant recipients. Transplantation2003; 75: 2086\u20132090","DOI":"10.1097\/01.TP.0000068868.01424.61"},{"key":"key\n\t\t\t\t20171012173145_BIB20","doi-asserted-by":"crossref","unstructured":"Midtvedt K, Fauchald P, Bergan S et al. C2 monitoring in maintenance renal transplant recipients: is it worthwhile? Transplantation2003: 76: 2086\u20132090","DOI":"10.1097\/01.TP.0000085046.39523.D5"},{"key":"key\n\t\t\t\t20171012173145_BIB21","doi-asserted-by":"crossref","unstructured":"Lemahieu WP, Maes BD, Verbeke K, Vanrenterghem YF. Alterations of CYP3A4 and P-glycoprotein in vivo with time in renal graft recipients. Kidney Int2004; 66: 433\u2013440","DOI":"10.1111\/j.1523-1755.2004.00750.x"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ndt\/article-pdf\/21\/1\/197\/5148311\/gfi113.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,4]],"date-time":"2025-01-04T18:01:10Z","timestamp":1736013670000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/ndt\/article\/21\/1\/197\/1818952\/Evolution-of-the-absorption-profile-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,10,4]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2005,10,4]]},"published-print":{"date-parts":[[2006,1,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfi113","relation":{},"ISSN":["1460-2385","0931-0509"],"issn-type":[{"type":"electronic","value":"1460-2385"},{"type":"print","value":"0931-0509"}],"subject":[],"published-other":{"date-parts":[[2006,1]]},"published":{"date-parts":[[2005,10,4]]}}}